Is a 25–35 % probability of a borderline HSV‑2 IgG result considered a high chance of true early HSV‑2 infection?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: October 1, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Ask Question

No, a 25-35% probability is NOT a high chance of true early HSV-2 infection—it represents a substantial risk of false-positive results that mandates confirmatory testing.

Understanding the Problem with Borderline HSV-2 Results

A borderline or low-positive HSV-2 IgG result (typically index values 1.1-3.0) has extremely poor specificity, meaning the majority of these results are false positives. According to the 2022 CDC guidelines, HSV-2 IgG tests with index values of 1.1-2.9 have only 39.8% specificity, while even index values ≥3.0 only achieve 78.6% specificity 1. This means:

  • At index values 1.1-2.9: approximately 60% are false positives
  • At index values 3.0-3.5: approximately 20% are false positives
  • Even at index values >3.5, false positives still occur 1

Why 25-35% Represents a LOW Chance

If you're being told there's a 25-35% probability of true infection with a borderline result, this actually means:

  • 65-75% chance the result is FALSE POSITIVE
  • This is far too high a false-positive rate to make a definitive diagnosis
  • HSV-2 is a chronic, lifelong infection with significant psychosocial impact—misdiagnosis causes substantial harm 1

Critical Clinical Action Required

All borderline HSV-2 IgG results (index value <3.0) MUST be confirmed with a second assay using a different glycoprotein G antigen before informing the patient of results 1. The recommended approach:

Confirmatory Testing Strategy:

  1. First-line confirmation: Use Biokit HSV-2 rapid assay

    • Improves specificity from 93.2% to 98.7% when combined with HerpeSelect
    • Improves positive predictive value from 80.5% to 95.6% 1

  2. Alternative confirmation: Western blot (gold standard)

    • Use when Biokit unavailable
    • Most accurate but limited accessibility 1

  3. If confirmatory testing unavailable:

    • Do NOT report positive results to patients with index <3.0
    • Consider retesting at 12 weeks if within window period of exposure 1

Important Caveats

HSV-1 co-infection increases false-positive risk: Patients with HSV-1 antibodies are significantly more likely to have false-positive HSV-2 results at low index values 1, 2. Recent research shows that indeterminate inhibition assay results (which represent false positives) are strongly associated with higher HSV-1 IgG levels 2.

Window period considerations: If testing occurs within 12 weeks of potential exposure, a negative or low-positive result may represent early seroconversion rather than false-positive. The sensitivity of HSV-2 serology is 92%, but antibodies may not be detectable for up to 12 weeks post-infection 1. In this scenario:

  • Repeat testing at 12 weeks post-exposure
  • Consider IgM testing (though IgM has limitations and is not routinely recommended)

Recent evidence confirms ongoing problems: A 2019 study found that 20% of false-positive sera had index values >3.5 in HerpeSelect, and 39% had indices >3.5 in Liaison assays 3. A 2024 study demonstrated that nearly one in three positive DiaSorin HSV-2 IgG results would be falsely positive in the general U.S. population 4.

Bottom Line

Do not diagnose HSV-2 infection based on a borderline result with only 25-35% probability of being true positive. This represents unacceptably high false-positive rates that will lead to misdiagnosis, unnecessary treatment, psychological distress, and disclosure complications. Always confirm with a second assay or Western blot before communicating results to patients.

References

Related Questions

What does a low HSV‑2 IgG level of 1.11 U/mL from Quest Diagnostics with an unmeasurable inhibition assay indicate when measured four weeks after a confirmed HSV‑2 exposure?
My HSV serology shows positive IgG for HSV‑1 (10.9) and HSV‑2 (1.53) and an indeterminate IgM for HSV‑2 pending; what does this indicate and how should I manage it?
After exposure to herpes simplex virus type 2 (HSV‑2), what is the earliest time that IgM and IgG antibodies can be detected on a blood test?
What does a herpes simplex virus type 2 (HSV‑2) IgG index of 9 indicate, and how should an asymptomatic patient be managed?
What does a low HSV‑2 IgG of 1.11 (with non‑measurable inhibition) obtained four weeks after a confirmed HSV‑2 exposure indicate, given the patient also has a high HSV‑1 IgG (~9)?
What is the diagnosis and recommended treatment for a patient with no osseous contusion or fracture, an intact Lisfranc ligamentous complex, no tarsometatarsal joint subluxation, diffuse dorsal midfoot/forefoot subcutaneous edema, mild naviculocuneiform joint chondrosis, and mild first webspace intermetatarsal bursitis?
What is the appropriate insulin regimen and adjunct therapy for a high‑cardiovascular‑risk patient currently on NPH (neutral protamine Hagedorn) and regular insulin who has inadequate glycemic control?
Which laboratory values, when low, indicate the need for referral to hematology‑oncology, and what is the rationale for each?
What is the recommended duration of doxycycline therapy for an otherwise healthy adult with uncomplicated atypical pneumonia?
Is oral cefixime (400 mg daily) combined with metronidazole (500 mg three times daily) appropriate for treating colonic diverticulitis with a small pericolic air pocket in a patient without generalized peritonitis, sepsis, severe comorbidity, and with normal renal and hepatic function?
How do estrogen and progesterone affect sleep architecture?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.